Comprehensive mutational profiling in advanced systemic mastocytosis

Juliana Schwaab, Susanne Schnittger, Karl Sotlar, +17

Blood

Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis

Mohamad Jawhar, Juliana Schwaab, Susanne Schnittger, +14

Leukemia

Additional MutationsMast Cell DisorderSystemic MastocytosisPathogenesisImmunology +5

The KIT D816V expressed allele burden for diagnosis and disease monitoring of systemic mastocytosis

Philipp Erben, Juliana Schwaab, Georgia Metzgeroth, +15

Annals of Hematology

SclerodermaMast Cell DisorderDiagnosisPathologyKit D816v +3

Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event

Mohamad Jawhar, Juliana Schwaab, Susanne Schnittger, +13

Leukemia

ImmunogeneticsMedicineMast Cell DisorderImmunologyMyeloid Neoplasia +9

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis

Mohamad Jawhar, Juliana Schwaab, Iván Álvarez‐Twöse, +22

Journal of Clinical Oncology

Response and progression on midostaurin in advanced systemic mastocytosis: KIT D816V and other molecular markers

Mohamad Jawhar, Juliana Schwaab, Nicole Naumann, +10

Blood

The clinical and molecular diversity of mast cell leukemia with or without associated hematologic neoplasm

Mohamad Jawhar, Juliana Schwaab, Manja Meggendorfer, +11

Haematologica

Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis

Mohamad Jawhar, Juliana Schwaab, Daniel Hausmann, +12

Leukemia

Srsf2/asxl1/runx1 Gene PanelMast Cell DisorderSystemic MastocytosisAlkaline PhosphatasePathology +3

Global Classification of Mast Cell Activation Disorders: An ICD-10-CM–Adjusted Proposal of the ECNM-AIM Consortium

Peter Valent, Karin Hartmann, Patrizia Bonadonna, +29

The Journal of Allergy and Clinical Immunology In Practice

Limited duration of complete remission on ruxolitinib in myeloid neoplasms with PCM1-JAK2 and BCR-JAK2 fusion genes

Juliana Schwaab, Marcin Knut, Claudia Haferlach, +12

Annals of Hematology

Hematological MalignancyTumor BiologyBcr-jak2 Fusion GenesMedicineHematology +7